Previous 10 | Next 10 |
2023-12-21 11:42:39 ET More on Immunovant, Roivant Sciences, etc. 2024 - Liquidia, Burford, And Roivant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript Immunovant gain...
2023-12-21 07:15:02 ET Deutsche Bank analyst issues BUY recommendation for IMVT on December 21, 2023 07:36AM ET. The previous analyst recommendation was Buy. IMVT was trading at $36.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical tri...
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical tri...
2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...
2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...
2023-12-14 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-05 14:25:03 ET Summary Analyzing 13F filings can provide a comprehensive overview of market sentiment and provide a stronger basis for making better-informed investment decisions. Today, we analyze and aggregate 13F filings from the end of the third quarter, seeking o...
2023-11-28 15:30:17 ET More on Immunovant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrad...
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study IMVT-1402 600 mg was observed to deliver ...
News, Short Squeeze, Breakout and More Instantly...
Immunovant Inc. Company Name:
IMVT Stock Symbol:
NASDAQ Market:
Biohaven Ltd’s (NYSE:BHVN) shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV...
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fi...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...